Press releases – 鶹ƽ Developing therapeutics for diseases with impaired kidney function Fri, 23 Jan 2026 14:08:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 https://i0.wp.com/www.enyopharma.com/wp-content/uploads/2016/02/cropped-enyo_pharma_large_app_icon.png?fit=32%2C32&ssl=1 Press releases – 鶹ƽ 32 32 231983735 鶹ƽ announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit /pr_alpestria-1_topline-data/ Fri, 16 Jan 2026 14:17:50 +0000 /?p=6212

    • Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline
    • 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect
    • Company plans to advance vonafexor to Phase 3 in Alport Syndrome

    Lyon, France – January 8, 2026 – 鶹ƽ (“ENYO”),

    Read more »]]>     6212     鶹ƽ announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients /enyo-pharma-pr-series-c-2025/ Thu, 12 Jun 2025 14:47:29 +0000 /?p=5935
  • 鶹ƽ completes €32 million Series C with new €6 million investment from Vesalius Biocapital IV
  • New funds will support two additional clinical studies and expand preclinical research, including in ADPKD
  • Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport syndrome confirmed for Q4 2025

    • Lyon, France – June 12, 2025 – 鶹ƽ (“ENYO”), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases,

    Read more »]]>     5935     鶹ƽ announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome /press_release_2024-01-03/ Wed, 03 Jan 2024 14:24:23 +0000 http://www.enyopharma.com/?p=4730
  • The Company will initiate a Phase 2 clinical study of Vonafexor in Alport Syndrome (called “ALPESTRIA-1”) in the first half of 2024.
  • Series C proceeds will fund the Phase 2 study, as well as operations and further R&D through the first half of 2026.

    • Lyon, France – January 3, 2024 – 鶹ƽ (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S.

    Read more »]]>     4730     鶹ƽ Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting /enyo-pharma-announces-two-vonafexor-data-presentations-at-aasld-the-liver-meeting/ Wed, 03 Nov 2021 13:17:55 +0000 http://www.enyopharma.com/?p=3966 Lyon, France. November 3rd, 2021 – 鶹ƽ (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.

    Read more »]]>     3966     鶹ƽ Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients /enyo-pharma-announces-16-weeks-vonafexor-eyp001-top-line-interim-results-from-two-on-going-phase-2a-studies-in-chronic-hepatitis-b-patients/ Fri, 30 Jul 2021 11:17:22 +0000 http://www.enyopharma.com/?p=3849 Lyon, France. July 30, 2021 – 鶹ƽ (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB).

    Read more »]]>     3849     鶹ƽ Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks /enyo-pharma-announces-positive-vonafexor-eyp001-results-for-the-livify-phase-2a-study-in-f2-f3-nash-patients-over-12-weeks/ Wed, 28 Jul 2021 12:23:04 +0000 http://www.enyopharma.com/?p=3842 Lyon, France. July 28, 2021 – 鶹ƽ, a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary and several secondary endpoints in the LIVIFY clinical study conducted in F2-F3 Non Alcoholic Steato-Hepatitis (NASH) patients.

    Read more »]]>     3842     Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats /europes-largest-initiative-launches-to-accelerate-therapy-development-for-covid-19-and-future-coronavirus-threats/ Tue, 18 Aug 2020 13:57:03 +0000 http://www.enyopharma.com/?p=3495 Brussels, Belgium – 18 August 2020 – CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners.

    Read more »]]>     3495     ENYO PHARMA ANNOUNCES MULTIPLE EYP001 DATA PRESENTATIONS AT AASLD CONFERENCE /enyo-pharma-announces-multiple-eyp001-data-presentations-at-aasld-conference/ Thu, 17 Oct 2019 13:19:46 +0000 http://www.enyopharma.com/?p=3323 Lyon, France. October 17, 2019 – 鶹ƽ will be present at the AASLD in Boston in November to present four Posters and one Oral presentation For its Lead Compound EYP001. ENYO will also hold KOL Symposium to Provide Scientific Update on Potential Benefits of FXR Agonists for HBV treatment, on the 10th of November.

    Read more »]]>     3323     ENYO PHARMA ANNOUNCES MOVE TO NEW CORPORATE HEADQUARTERS /enyo-pharma-announces-move-to-new-corporate-headquarters/ Thu, 03 Oct 2019 13:36:32 +0000 http://www.enyopharma.com/?p=3208 Lyon, France., October 3rd, 2019 – 鶹ƽ, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company’s headquarters to the 8th Arrondissement in Lyon in the BIOSERRA buildings at 60 avenue Rockefeller, to support long-term growth and advancement of pipeline.

    Read more »]]>     3208     ENYO PHARMA ANNOUNCES NEW CFO AND PROVIDES CLINICAL PIPELINE UPDATE /enyo-pharma-announces-new-cfo-and-provides-clinical-pipeline-update/ Thu, 19 Sep 2019 13:08:35 +0000 http://www.enyopharma.com/?p=3164 Lyon, France, September 19th, 2019 – 鶹ƽ, a private clinical stage biotechnology company developing innovative drug candidates, today announced the appointment of Jonathan Lieber as Chief Financial Officer. 鶹ƽ also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company’s FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH).

    Read more »]]>     3164